Back to results
US 2019/0099393 A1Published application
Treatment for Therapy Refractory Depression
OwnerHarald Murckinventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerHarald Murckinventor
Estimating the term…
A method treats patient with treatment resistant depression, adjunct to standard antidepressant treatment or as monotherapy. These patients will be identified by non-response to at least one pharmacological antidepressant treatment with a sufficient dose and over a sufficient period of time. Further, one embodiment of the method includes a procedure to identify patients who would benefit from a combination of standard antidepressants with the described compounds from the start of the treatment in order to maximize the likelihood of response. Another embodiment of the method combines the described compounds with forms of Magnesium salts in order to overcome longer term tolerability issues with the compounds. An important downstream mechanism of the described interventions is the property to reduce the production and or increase the absorption of cerebrospinal fluid to treat a variety of symptoms, including cognitive dysfunction, memory loss, apathy, sleep disturbances, pain disorders, and somatoform pain and headache.
A method for treating therapy refractory depression, comprising administering to a subject a preparation comprising a first compound having 11-beta-HSD-2 inhibitory activity.
A method for treating therapy refractory depression, comprising co-administering an inhibitor of 11-beta-HSD-2 or metabolites thereof with an antidepressant drug.
A method for treating therapy refractory depression, comprising co-administering an inhibitor of 11-beta-HSD-2 or metabolites thereof as monotherapy.
A method for treating therapy refractory depression, memory dysfunction, cognitive dysfunction, anxiety, somatization, depression, amotivational syndrome, obesity, sleep disturbances, pain disorders, and somatoform pain and headache, as well as gait disturbance and bladder dysfunction, comprising co-administering a composition to reduce the secretion rate of cerebrospinal fluid (CSF).
A method in which a treatment with an inhibitor of 11-beta-HSD-2 or an inhibitor of cerebrospinal fluid (CSF) production targets one or more CNS symptoms other than depression, which CNS symptoms have a related mechanism of action, wherein the CNS symptoms comprise anxiety, cognitive dysfunction, memory loss, apathy, sleep disturbances, pain disorders, and somatoform pain and headache, as well as obesity, gait disturbance and bladder dysfunction.
Dependencies are inferred from the claim text.